Last reviewed · How we verify
cardiomyopeptidin
Cardiomyopeptidin, developed by the Chinese PLA General Hospital, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but its key strength lies in its current market availability. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | cardiomyopeptidin |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Randomized, Single-blind, Controlled Clinical Study of Cardiomyopeptidin on Improving Ischemia-reperfusion Injury in Patients With Acute ST-segment Elevation Myocardial Infarction After Primary PCI (PHASE4)
- The Cardio-protective Effect of Cardiomyopeptidin on Myocardial Injury in ICU Patients With Non-organic Heart Disease: a Prospective, Single-blind, Randomized Controlled Pilot Study (PHASE4)
- Clinical Study of Cardiomyopeptidin on Postoperative Ischemia-reperfusion Injury in Patients With Primary PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cardiomyopeptidin CI brief — competitive landscape report
- cardiomyopeptidin updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI